| Aquaporin-4 (AQP4) | |
|---|---|
| Gene | AQP4 |
| UniProt | P55087 |
| PDB Structures | 3GD8, 2D57 |
| Molecular Weight | ~34 kDa (M1 isoform, monomer) |
| Localization | Plasma membrane; highly polarized to astrocyte perivascular endfeet |
| Protein Family | Aquaporin (MIP) water channel family |
| Diseases | Alzheimer's Disease, NMO (Devic's Disease), TBI, Cerebral Small Vessel Disease |
Aquaporin 4 (Aqp4) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Aquaporin-4 (AQP4) is a ~34 kDa transmembrane water channel protein encoded by the AQP4 gene on chromosome 18q11.2. [It is the most abundant aquaporin in the central nervous system and the principal mediator of transmembrane water flux in the brain. AQP4 is expressed predominantly in [astrocytes[/cell-types/astrocytes, with a striking polarization to perivascular endfeet — the astrocytic membranes that ensheath cerebral blood vessels — where it facilitates water exchange between the perivascular and interstitial compartments ([Nagelhus & Bhatt, 2013]https://doi.org/10.1152/physrev.00011.2013)).
AQP4's critical role in the brain's waste clearance machinery was revealed by the discovery of the glymphatic system — a perivascular pathway that drives convective flow of cerebrospinal fluid (CSF) through brain parenchyma to clear metabolic waste, including [Amyloid-Beta[/proteins/Amyloid-Beta and tau]/proteins/tau (Iliff et al., 2012). AQP4 knockout mice show a ~65% reduction in interstitial solute clearance, and loss of perivascular AQP4 polarization is observed in aging and [Alzheimer's disease[/diseases/alzheimers, contributing to impaired waste removal and accumulation of neurotoxic proteins (Mestre et al., 2018).
AQP4 is also the target antigen in neuromyelitis optica spectrum disorder (NMOSD), an autoimmune [demyelinating disease] where pathogenic AQP4-IgG antibodies cause severe astrocyte destruction and inflammatory [demyelination[/mechanisms/demyelination.
The crystal structure of human AQP4 at 1.8 Å resolution reveals the canonical aquaporin fold (Ho et al., 2009):
AQP4 assembles into homotetramers, with each monomer forming an independent water pore. Uniquely among aquaporins, AQP4 tetramers further organize into supramolecular structures called orthogonal arrays of particles (OAPs) — large, regular two-dimensional lattices in the plasma membrane that can be visualized by freeze-fracture electron microscopy (Bhatt & Bhatt, 2003).
The size and stability of OAPs are determined by the ratio of two major AQP4 isoforms:
| Isoform | Start | Size | OAP Formation | Localization |
|---|---|---|---|---|
| M1 | Met-1 | 323 aa | Restricts OAP size; forms small, unstable arrays | Widely distributed |
| M23 | Met-23 | 301 aa | Promotes large, stable OAPs through N-terminal interactions | Enriched in perivascular endfeet |
| AQP4ex | Readthrough | 326 aa | C-terminal extension; modulates OAP anchoring | Perivascular endfeet |
M23 is the dominant isoform in astrocyte perivascular endfeet, where it forms large OAPs anchored to the dystrophin-associated protein complex (DAPC) via [α-syntrophin]. This anchoring system maintains AQP4 polarization — the critical feature for glymphatic function.
A translational readthrough isoform, AQP4ex, extends the C-terminus by 29 amino acids past the normal stop codon. AQP4ex is selectively enriched in perivascular endfeet and is required for proper OAP anchoring and AQP4 polarization. Loss of AQP4ex disrupts perivascular localization and impairs glymphatic clearance, making it a potential therapeutic target for [Alzheimer's disease[/diseases/alzheimers and other [proteinopathies] (De Bellis et al., 2023).
AQP4 is the primary regulator of water transport across the blood-brain interface and the brain-CSF barriers:
The [glymphatic system[/entities/glymphatic-system depends on AQP4 for efficient waste clearance (Iliff et al., 2012):
AQP4-null mice show:
Glymphatic clearance is dramatically enhanced during sleep — interstitial space volume increases by ~60% during slow-wave sleep, facilitating convective flow. AQP4-mediated water transport is central to this process, linking [sleep disturbance] to impaired [Aβ[/entities/amyloid-beta clearance and AD risk (Xie et al., 2013).
AQP4 co-localizes with [Kir4.1] potassium channels in astrocyte endfeet. Together they maintain potassium spatial buffering — redistributing extracellular K⁺ released during [neuronal activity] to prevent [excitotoxicity[/entities/excitotoxicity. AQP4 deletion in mice causes impaired K⁺ clearance and lowered seizure threshold.
AQP4 dysfunction is increasingly recognized as a contributor to AD pathogenesis through impaired glymphatic waste clearance:
Loss of perivascular polarization: In postmortem AD brains, AQP4 is redistributed away from perivascular endfeet to the cell body and non-perivascular processes — a phenomenon termed "loss of AQP4 polarization" (Zeppenfeld et al., 2017). This mislocalization impairs the driving force for glymphatic flow, reducing [Aβ[/entities/amyloid-beta and tau clearance.
Genetic association: AQP4 single-nucleotide polymorphisms (SNPs) modify AD risk and progression. A 2020 study demonstrated that specific AQP4 variants predict amyloid burden and cognitive trajectory in the AD spectrum (Burfeind et al., 2020), and a 2025 study linked AQP4 SNPs to longitudinal changes in white matter free water content in older adults (Katsuse et al., 2025).
CSF AQP4 as biomarker: CSF AQP4 levels are elevated in AD and other neurodegenerative dementias, potentially reflecting astrocyte endfeet damage and compensatory shedding. Elevated CSF AQP4 correlates with markers of glymphatic dysfunction (Lesauvage et al., 2022).
[Tau[/entities/tau-protein pathology: AQP4 deletion in tau transgenic mice dramatically exacerbates tau pathology] and [neuronal loss], demonstrating that glymphatic clearance is critical for tau homeostasis.
In [NMOSD[/diseases/nmosd, pathogenic IgG autoantibodies target the extracellular loops of AQP4 (NMO-IgG / AQP4-IgG), preferentially binding the OAP conformation of M23:
AQP4 plays a dual role in brain edema following [traumatic brain injury[/diseases/traumatic-brain-injury:
In [cerebral small vessel disease[/diseases/cerebral-small-vessel-disease and aging, loss of AQP4 perivascular polarization correlates with white matter hyperintensities and enlarged perivascular spaces, reflecting impaired glymphatic function.
Strategies to restore or enhance AQP4-dependent glymphatic clearance:
| Approach | Mechanism | Status |
|---|---|---|
| AQP4 polarization restoration | Re-anchor AQP4 to perivascular endfeet via DAPC modulators | Preclinical concept |
| AQP4ex modulation | Enhance readthrough isoform to improve endfeet anchoring | Early preclinical |
| Sleep optimization | Leverage sleep-enhanced glymphatic clearance | Clinical lifestyle intervention |
| Low-dose alcohol | Moderate ethanol exposure enhances glymphatic flow in mice | Preclinical; epidemiological support |
| Posture optimization | Lateral sleep position enhances glymphatic clearance | Preclinical |
The study of Aquaporin 4 (Aqp4) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.